Home | About | RRTC & CTPs | Protocols | Directory


Regional Research Training Center

Leadership of the PN Node | Additional Core RRTC Staff | Affiliated Investigators

Leadership of the Pacific Northwest Node

Dennis Donovan, Ph.D.
Principal Investigator and Project Director
Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 120, Box 354805
Seattle, WA 98105-4631
tel: 206-543-0937
e-mail: ddonovan@u.washington.edu

The leadership of the Washington Node RRTC provides a unique collective strength in administration, research, and community practice. Dennis Donovan, Ph.D. serves as Principal Investigator and Director of the RRTC. Dr. Donovan is a Professor in the Department of Psychiatry and Behavioral Sciences, an Adjunct Professor in the Department of Psychology, and the Director of the University of Washington Alcohol and Drug Abuse Institute (ADAI). Dr. Donovan has over 25 years experience as a direct service provider, clinical trainer and supervisor, program administrator, and clinical researcher in the substance abuse field. He has expertise in motivational interventions, cognitive and behavioral interventions such as relapse prevention, client-treatment matching, treatment outcome evaluation, and services research. Dr. Donovan's role as PI for the Seattle clinical research units in two NIAAA-funded multi-site studies, Project MATCH and Project COMBINE, have uniquely prepared him for his role as PI for the Washington node. In this role, he participated in, and chaired, a number of study committees making decisions about protocol development and implementation, primary and secondary hypotheses, recruitment strategies, inclusion/exclusion criteria, assessment instruments and schedule, the therapies to be evaluated, data analysis and publication policies and plans, and overall trial and site-specific budgets. He participated in manualization of therapies and development of measures of treatment integrity and therapist competence. As director of ADAI, Dr. Donovan has collaborated extensively with the Washington State Division of Alcohol and Substance Abuse (DASA) in planning and conducting evaluations of community-based treatment programs in Washington State. He has overall administrative responsibility for the operational, fiscal, and scientific conduct of the RRTC. As the Director of the Alcohol and Drug Abuse Institute, he is in a position to facilitate the integration of the RRTC and Node within the University of Washington administrative structure. Dr. Donovan's ability to oversee complex, multifaceted projects and budgets has been demonstrated by the successful management of the Washington Node over the past six years of participation in the CTN.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Elizabeth (Betsy) Wells, Ph.D.
Co-Principal Investigator for Research, Scientific Director
Research Professor
University of Washington School of Social Work
4101 15th Ave. N.E.
Seattle, WA 98105
tel: 206- 616-7450
e-mail: bwells@u.washington.edu

Dr. Wells serves as the Co-PI for Research and the Scientific Director of the RRTC. She is a Research Professor in the University of Washington School of Social Work, where she also teaches courses on research design and methodology. She is also the School's Director of Research Operations and a Research Affiliate of ADAI, where her office is located. Additionally, Dr. Wells is currently a member of the NIDA Treatment Research Initial Review Group (NIDA-E). She previously served as Director of Research at Evergreen Treatment Services (ETS), one of the CTPs in the Pacific Northwest Node. In that capacity she served as site PI or PI in three studies conducted at ETS: a multisite trial of acupuncture treatment for cocaine dependence; a trial of motivational interviewing with street-recruited cocaine users; and a trial of motivational interviewing to reduce HIV and Hepatitis risk behavior among methadone waiting list patients. Dr. Wells has a long history of research in the areas of methadone maintenance, HIV/AIDS prevention, and cognitive, behavioral, and motivational interventions with opiate, cocaine, and stimulant abusers. For the past 15 years, she has conducted clinical trials research in collaboration with a variety of community-based treatment programs. She has had ongoing NIDA funding for her work, and has collaborated with a number of the members of the RRTC. Dr. Wells has expertise in cognitive and behavioral interventions, in design and implementation of clinical trials, in measurement of drug use and related variables, and in methods to enhance researcher/ CTP relationships. In the CTN, she recruits project-specific management committees comprised of scientists, RRTC staff and CTP representatives and is responsible for overseeing the scientific activities of the RRTC and its investigators, as well as the implementation of protocols in the CTPs.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
T. Ron Jackson, M.S.W.
Co-Principal Investigator for CTP Involvement

Evergreen Treatment Services
1700 Airport Way South
Seattle, WA 98134-1618
tel: 206-223-3644
e-mail: ronjack@u.washington.edu

Mr. Jackson is the Executive Director of Evergreen Treatment Services, a position he has held for over 25 years. ETS is a private, non-profit community-based organization providing adult outpatient opiate replacement treatment, drug-free treatment, and case management services at three clinics and a mobile van service, and serves as one of our Node's CTPs. Mr. Jackson serves as the Co-PI for CTP Involvement and is our CTP representative on the CTN Steering Committee. Mr. Jackson has extensive background in direct service provision, professional training and supervision, and treatment program administration. He has received considerable professional recognition for his contributions, as the recipient of the Nyswander-Dole Award from the American Association for the Treatment of Opioid Dependence (AATOD) in 2003 and a Lifetime Achievement Award from the Washington State Division of Alcohol and Substance Abuse in 2006. Mr. Jackson has been highly supportive of clinical research and the benefits that it can bring to clinical care and program planning. He played a prominent role in developing a strong working relationship with the treatment programs selected for participation as CTPs in the Washington Node. He also has had extensive experience as an educator and professional trainer, and holds the rank of Clinical Associate Professor in the University of Washington School of Social Work. Particularly relevant areas of his teaching are his focus on the use of the Addiction Severity Index as a standardized evaluation instrument and the clinical and administrative benefits that can be derived from program evaluation. His support is evidenced by the development of an active research program at Evergreen Treatment Services, where Dr. Wells serves as the Director of Research. It is this type of close, supportive, collaborative, and mutually beneficial relationship between researchers and community-based treatment programs that we hope to initiate, foster, and maintain across time with the other community treatment programs (CTPs) involved in our Node.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Andrew Saxon, M.D.
Co-Principal Investigator for Medication Trials

Psychiatry and Behavioral Sciences
University of Washington, Box 358280
VAMC Addiction Treatment Center
Bldg. 7, SVAMC (116DDTP)
1660 S. Columbian Way
Seattle, WA 98018
tel: 206-764-2782
e-mail: andrew.saxon@med.va.gov
Andrew J. Saxon, M.D., serves as the Co-PI for Medication Trials. Dr. Saxon is a Board Certified Addiction Psychiatrist, the Director of the Addictions Treatment Center at the VA Puget Sound Health Care System; prior to assuming this administrative position he served as the Medical Director of the Opiate Substitution Treatment Program. He is also a Professor in the Department of Psychiatry and Behavioral Sciences and Director of the University of Washington Addiction Psychiatry Residency Program . He is an expert in pharmacotherapy for substance dependence. In addition to conducting local clinical investigations on disulfiram, methadone, and valproic acid, Dr. Saxon has participated in the design and implementation of several national, multisite cooperative medication trials for treatment of alcohol, cocaine, and opioid dependence. He has worked on NIDA's multisite Buprenorphine/Naloxone safety trial, the VA multisite study of naltrexone for the treatment of alcohol dependence, and Project COMBINE, the NIAAA multisite, double blind, placebo-controlled, randomized clinical trial evaluating acamprosate and naltrexone, together with two types of behavioral interventions, in the treatment of alcohol dependence. In addition, he also has expertise in the areas of urine toxicology testing, HIV prevention, Hepatitis C, and operant conditioning treatment of opioid dependence. He also has collaborated extensively with Dr. Wells and Mr. Jackson in past research. In the CTN, Dr. Saxon has primary responsibility for the development, implementation, and conduct of medication / pharmacological trials within the node.

Additional Core RRTC Staff

John Baer, Ph.D.
Director of Training

Department of Psychology / VA Medical Center
Box 358280 - S116 - ATC
1660 S. Columbian Way
Seattle, WA 98108
tel: 206-768-5224
e-mail: jsbaer@u.washington.edu
Dr. Baer serves as the Director of Training in the Node. He is a Research Associate Professor in the Department of Psychology and the Associate Director for Education and Training and Director of Interdisciplinary Fellowship Training in the Treatment of Addictive Disorders at the VA National Center of Excellence in Substance Abuse Treatment and Education at the VA Puget Sound Health Care System. He is also a Research Affiliate of ADAI, where his office is located. He has been active in basic research on the etiology of alcohol and drug problems with adolescents and young adults, the development and evaluation of early interventions for such individuals, and best methods for training counselors in motivational interventions and other types of behavioral therapies. He has been involved in a number of research programs including Project COMBINE, in which he served as a primary supervisor for cognitive-behavioral therapists; a NIAAA-funded project using brief motivational interventions with street youth; a project funded as a small grant by ADAI evaluating the effect of a brief motivational intervention on treatment-seeking by incarcerated veterans who are substance abusers; and projects funded through the VA evaluating alcohol interventions for hepatitis-C patients. He is currently the PI on a NIDA-funded project, developed originally as a research concept for consideration in the CTN, to evaluate the efficacy of different methods of training motivational interviewing skills to drug abuse counselors in 8 CTPs within the PN Node. In addition, Dr. Baer performs several one- to two-day workshops each year teaching clinicians techniques of assessment, early intervention, and motivational interviewing. He has been certified as a motivational interviewing trainer, having completed “Training for Trainers” with Dr. William Miller.

Dr. Baer served as a member of the CTN Training Committee from our Node's entry into the CTN until the committee was disbanded and he now serves as the director of the Node's Training Unit. In the Node, Dr. Baer has primary responsibility for overseeing clinical and research training within the RRTC. He is also involved both at the level of the Node and the CTN in assisting in the development and manualization of cognitive, behavioral, and motivational therapies.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Donald A. Calsyn, Ph.D.
HIV/AIDS Specialist

Psychiatry and Behavioral Sciences
University of Washington
Addiction Treatment Center VAMC
Bldg 24, Rm 47 SVAMC (116DDTP) Box 358280
1660 S. Columbian Way
Seattle, WA 98108
tel: 206-764-2081
e-mail: calsyn@u.washington.edu
Dr. Calsyn is a Professor in the Department of Psychiatry and Behavioral Sciences and is a Research Affiliate of ADAI where his office is located. He is also a Fellow in Division 50 (Division on Addictions) of the American Psychological Association. He was previously the Director of Outpatient Services and of the Opiate Substitution Treatment Program at the Addictions Treatment Center of the VA Puget Sound Health Care System. He has been involved with clinical research focusing on methadone clients, their characteristics, and different approaches to their treatment, as well as on HIV/AIDS risk behaviors and preventive interventions among IV drug abusers. Dr. Calsyn was the Principal Investigator on two NIDA-funded clinical trials: "AIDS Prevention in IV Drug Users," conducted at the VA and at Evergreen Treatment Services and "Comparison of Three Levels of Methadone Intervention," conducted entirely at Evergreen Treatment Services. Dr. Calsyn has been an active member of the CTN HIV/AIDS SIG. He served as the national Lead Investigator for CTN0018 (Safer Sex for Men) and the co-Lead Investigator for CTN0019 (Safer Sex Skills for Women). He also served as the Node-level investigator for the health-services protocol CTN0012 (Infections) and the behavioral intervention protocol CTNCTN0017. Dr. Calsyn is also the PI of a NIDA-funded project, working with Dr. Merrill and other ADAI Research Scientists, examining prescription opioid misuse in the context of chronic pain treatment in a large health maintenance organization in the Pacific Northwest .
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Suzanne Doyle, Ph.D.
Statistician

Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 120, Box 354805
Seattle, WA 98105
tel: 206-616-2563
e-mail: srdoyle@u.washington.edu
Dr. Doyle is a Research Scientist at the Alcohol and Drug Abuse Institute, and is the Institute's biostatistician. She received her doctorate in biometry from the University of Texas Health Science Center in Houston. At ADAI, she consults with principal investigators and their research and data analysis staff on research design and statistical methods for evaluating the efficacy and/or effectiveness of interventions, and testing theoretical models related to substance abuse and its treatment and prevention. Within the CTN Pacific Northwest node, she works with local investigators and the Data Management Center to develop case report and other data collection forms, conduct interim analyses, conduct power analyses for complex study designs, and other types of statistical consultation. Prior to coming to ADAI, Dr. Doyle was a Research Scientist/Data Analyst for the Fast Track project in the UW Dept. of Psychology.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Mary Hatch-Maillette, Ph.D.
Project Coordinator

Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 114, Box 354805
Seattle, WA 98105

tel: 206-616-7730
e-mail: hatchm@u.washington.edu
Mary Hatch-Maillette, Ph.D., is a Research Scientist at the Alcohol and Drug Abuse Institute. She obtained her Ph.D. in Clinical Psychology at the University of Nebraska-Lincoln. She completed her clinical internship at the VA Medical Center in Seattle, followed by her clinical postdoctoral fellowship at the VA's Center for Excellence in Substance Abuse Treatment and Education (CESATE). Since 1994, Dr. Hatch-Maillette has collaborated on and overseen research projects focusing on gender and violence risk assessment, sex offenders, and ADHD. Her clinical work has specialized in the treatment of drug and alcohol addictions and Post Traumatic Stress Disorder. Dr. Hatch-Maillette has served as the National Project Director for CTN-0018 (Safer Sex for Men), for which the PN Node was the Lead Node. In addition to her national role, she served as the Node-level project director for both CTN-0018 and its companion protocol, CTN-0019 (Safer Sex for Women), CTN-0015 (Women & Trauma), and CTN-0030 (Prescription Opiate Analgesic Treatment Study). Additionally, she serves on the National operations group for CTN-0027 (START) working directly with the lead team on study implementation.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Lynn McIntosh
Liaison to the Northwest Addiction Technology Transfer Center
Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 120, Box 354805
Seattle, WA 98105-4631
tel: 206-616-1354
e-mail: mctosh@u.washington.edu
Ms. McIntosh has been on staff of the Northwest Frontier Addiction Technology Transfer Center (NFATTC) and housed at ADAI since 2004. The mission of this SAMHSA-funded project is to increase the knowledge and skills of addiction treatment practitioners by disseminating state-of-the-art research and by providing evidence-based workforce education. She is responsible for disseminating information derived from CTN research to substance abuse clinicians and treatment programs in Washington and Alaska. Prior to joining our staff she worked for the Northwest AIDS Education and Training Center, located at the University of Washington, which offers HIV treatment education, clinical consultation, capacity building and technical assistance to health care professionals and agencies in Washington, Alaska, Montana, Idaho, and Oregon. She had primary responsibility for working with programs and practitioners in Alaska.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Brenda Stuvek
Node Coordinator

Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 120, Box 354805
Seattle, WA 98105
tel: 206-685-6691
e-mail: bkhurley@u.washington.edu
Ms. Stuvek has served as our Node Coordinator since our entry into the CTN. She is responsible for facilitating communication within the RRTC and between the RRTC and administrative personnel in affiliated CTPs, project budgeting and fiscal monitoring, purchasing, coordinating travel arrangements for RRTC and CTP members, and other day-to-day operations of the RRTC. She prepares the 3-year budget projections that are requested periodically by the CCTN and collaborates on the preparation of progress reports, supplement and carryover requests, and NIH renewal applications. Ms. Stuvek has primary responsibility for overseeing the CTP subcontracts and reporting the status to Dr. Donovan and Merrilee Gavigan , ADAI's departmental administrator. She works directly with Dr. Donovan and Ms. Gavigan on administrative and budget matters. This process has been very successful and effective in keeping RRTC, Node, and protocol expenses within the projected budget, allowing us to accumulate and utilize carryover funds, and reducing the need for budgetary supplements. Ms. Stuvek also provides staff support for the Node SC, and assists with correspondence, manuals, manuscripts, and presentation materials.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Lisa R. Thomas, Ph.D.
Liaison to the Alaska CTP
Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 120, Box 354805
Seattle, WA 98105-4631
tel: 206-616-1354
e-mail: lrthomas@u.washington.edu

Dr. Thomas, an Alaska Native (Tlingit) whose family is from Southeast Alaska, is a clinical psychologist trained in addictions treatment and research, and a Research Scientist at ADAI. She is the Chair-Elect of the American Psychological Association's Committee on Ethnic Minority Affairs. She is the Co-PI and Project Director on a grant with Dr. Donovan, funded by NIH's National Center on Minority Health and Health Disparities, to use community-based participatory research methods to develop and test culturally relevant prevention/intervention strategies for substance abuse problems among Native American youth in the Suquamish Tribe across Elliot Bay from Seattle. She was previously a Research Associate at the Center for Alaska Native Health Research at the University of Alaska – Fairbanks , involved in the NIAAA-funded People Awakening Project. Dr. Thomas has clinical experience as a mental health counselor in the Native American Counseling Center, Seattle Indian Health Board. She has provided consultation and evaluation services to the Central Council Tlingit and Haida Indian Tribes of Alaska Wellness Project in which she monitored community-based wellness programs in nineteen isolated, rural Tlingit communities in Southeast Alaska . She also has been an evaluator for the Cook Inlet Tribal Council. Dr. Thomas has participated with Dr. Donovan in discussions and a site-visit to SEARHC, the Alaska CTP that is joining our node, and she will continue to serve a liaison role for that CTP.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Nancy Sutherland, MLS
Dissemination Librarian
Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 120, Box 354805
Seattle, WA 98105-4631
tel: 206-685-9464
e-mail: info@ctndisseminationlibrary.org
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Meg Brunner, MLIS
Dissemination Librarian
Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 120, Box 354805
Seattle, WA 98105-4631
tel: 206-543-0937
e-mail: info@ctndisseminationlibrary.org

Affiliated Investigators

Betty Buchan, Ph.D.
Assistant Professor of Public Health
University of Alaska, Anchorage
3211 Providence Dr., DPL 404
Anchorage, AK 99508-4614
tel: 907-786-6574
e-mail: Betty.Buchan@uaa.alaska.edu
Dr. Buchan is an Assistant Professor of Public Health in the Department of Health Sciences, University of Alaska, Anchorage. Prior to moving to Alaska in 2003, she was an adjunct Assistant Research Professor at the University of South Florida, Tampa, FL, and from 1999 to 2003 was the Vice President for Research and Laboratory Services at Operation PAR, a CTP affiliated with the Florida Node of the CTN. She served as the Principal Site Investigator for CTN-0001 (Buprenorphine versus Clonidine for Inpatient Opiate Detoxification). She also served as the Site Investigator on a CSAT-funded project evaluating the relative effectiveness and cost effectiveness of various interventions targeted at reducing adolescent marijuana use. In Alaska she is on the Boards of Directors of the Alaska Public Health Association and the Narcotic Drug Treatment Center, Inc. (Center for Drug Problems). She also served as the Director of Research for the Southcentral Foundation in Anchorage. Her addition to the Pacific Northwest Node provides an academic collaborator in Alaska with a working knowledge of the CTN, allowing us to more effectively support trials at the new Alaska CTP, with which she already has developed working relationships. She also brings additional experience conducting pharmacotherapy trials, and expertise in treatment of marijuana abuse/dependence among adolescents.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Daniel R. Kivlahan, Ph.D.
Co-Investigator for Health Services Studies

Psychiatry and Behavioral Sciences
University of Washington
VA Puget Sound Health Care System (116 MATCH)
1660 Columbian Way S., Box 358280
Seattle, WA 98108
tel: 206-768-5483
e-mail: kivlahan@u.washington.edu
Dr. Kivlahan is an Associate Professor in the Department of Psychiatry and Behavioral Sciences and Adjunct Associate Professor in the Department of Psychology. He is the Director of the VA National Center of Excellence in Substance Abuse Treatment and Education (CESATE), and Associate Director for Health Services Research in the Mental Illness Research, Education, and Clinical Center (MIRECC) located at the VA Medical Center in Seattle. The CESATE, in conjunction with the MIRECC, has developed a prominent role in conducting and providing consultation on health services research within the VA substance abuse treatment system nationally. He is also a member of the VA National Health Services Research and Development (HSR&D) research review board and an investigative affiliate of the VA Northwest Health Services Research and Development Center of Excellence at the Seattle VA Medical Center. In addition to his focus on health services issues, he has investigated the effectiveness of skill building interventions in the prevention and treatment of alcohol problems.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Antoinette Krupski, Ph.D.
Center for Healthcare Improvement for Addictions, Mental Illness & Medically Vulnerable Populations
Harborview Hospital, Box 359911
325 9th Avenue
Seattle, Washington 98104-2499
tel: 206-341-4215
e-mail: krupski@u.washington.edu
Dr. Krupski is Research Associate Professor in the Department of Psychiatry and Behavioral Sciences and Associate Director of the Center for Health Care Improvement for Addictions, Mental Illness and Medically Vulnerable Populations (CHAMMP) at Harborview Medical Center in Seattle. Before assuming this position in October 2006, she had served since 1991 as the Research Administrator for the Washington State Division of Alcohol and Substance Abuse (DASA). There, Dr. Krupski oversaw and coordinated research/evaluation efforts that drove prevention and treatment policies, planning, and practices undertaken by DASA. During this time, she managed over 50 statewide evaluations of chemical dependency treatment (including treatment outcomes of indigent persons, pregnant women, SSI recipients, mentally ill chemically abusing persons, persons committed involuntarily to treatment, individuals in opiate substitution programs) based on analyses of secondary data as well as primary self-report data. She maintained a statewide research committee of over 70 substance abuse researchers who met with state officials and policy makers three times a year. In 1998, she was appointed chair of a 19-state Steering Committee for the TOPPS II Project (State Treatment Outcomes and Performance Pilot Studies Enhancement) funded by CSAT. Since 1998, she has also served as a member of the National Evaluation Data Services (NEDS) Expert Panel for CSAT. She also has served as a consultant to the Center for Advancing Longitudinal Research on Drug Abuse (CALRDA), University of California, Los Angeles, and as a member of the Technical Consultation Group, State Outcomes Measurement and Management System (SOMMS), Substance Abuse and Mental Health Services Administration.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Joseph Merrill, M.D., M.P.H.
Medicine/Division of General Internal Medicine
University of Washington
Box 359780
Seattle, WA 98105
tel: 206-731-4605
e-mail: joem@u.washington.edu
Dr. Merrill is a Clinical Assistant Professor in the Department of Medicine/Division of General Internal Medicine at Harborview Medical Center in Seattle. He is an internal medicine physician with clinical and research experience in the medical care of drug users, HIV/AIDS and palliative care, pain management, prescription opiate dependence, and the integration of addiction treatment into primary care. Prior to coming to the University of Washington as a Robert Wood Johnson (RWJ) Clinical Scholar, he was the Director of HIV Medical Services, San Francisco General Hospital Methadone Clinic. He has received funding from the RWJ Substance Abuse Policy Research Program to develop, implement, and evaluate a pilot project of office-based methadone maintenance in a primary care program. This collaborative project involved working closely with community-based treatment programs, including Evergreen Treatment Services, health care facilities, and regulatory agencies at the federal, state and local levels. A second RWJ-funded project is studying the policy and protocol development of a pilot office-based buprenorphine program for Washington State Medicaid patients.  He is also currently involved with a third RWJ-funded project studying Medicaid policies for buprenorphine and is working with Dr. Calsyn on a NIDA-funded project examining prescription opioid misuse in the context of chronic pain treatment in a large health maintenance organization in the Pacific Northwest.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Richard K. Ries, M.D.
Co-Investigator for Dual Disorders Studies

Psychiatry and Behavioral Sciences
University of Washington
2HH-20 Harborview Medical Center, Box 359911
Seattle, WA 98104
tel: 206-731-2841
e-mail: rries@u.washington.edu
Dr. Ries is Director of Outpatient Psychiatry and Dual Disorders programs at Harborview Medical Center in Seattle. He is Professor in the Department of Psychiatry and Behavioral Sciences and Director of the Department's Division on Addictions. He is also the Medical Director for the Washington State Division of Alcohol and Substance Abuse (DASA). He has specialty certification in Addiction Medicine by the American Society on Addiction Medicine (ASAM) and is Board Certified in Addiction Psychiatry. Together with Dr. Saxon, he co-directs the Department's fellowship in addiction psychiatry and coordinates the addictions clinical rotations for the Psychiatry Residency program. He also chairs the Committee for Substance Abuse Education, University of Washington, School of Medicine, which is responsible for integrating training and education on addictions into the School of Medicine 's medical student curriculum. He has a primary interest in dual disorders. He chaired CSAT's expert consensus panel that developed the Treatment Improvement Protocol for dual disorders (TIP No. 9, Assessment and Treatment of Patients with Coexisting Mental Illness and Alcohol and Other Drug Abuse) and co-chaired the consensus panel in the development of TIP 42 (Substance Abuse Treatment for Persons With Co-Occurring Disorders). He also worked on NIDA's multisite Buprenorphine/Naloxone safety trial and is the medical director for a current NIDA project evaluating suboxone and Dialectic Behavior Therapy (DBT) for subjects with both Borderline Personality Disorders and opiate dependence. He and Dr. Donovan have worked previously on the development of screening and brief interventions delivered in medical trauma centers.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Roger Roffman, D.S.W.
Co-Investigator for Cognitive-Behavioral Intervention Studies

Social Work
University of Washington
225-C Social Work, 4101 15th Ave NE
Box 354900
Seattle, WA 98105
tel: 206-543-5968
e-mail: roffman@u.washington.edu
Dr. Roffman is Director of the Innovative Programs Research Group and Professor in the School of Social Work. He has a long history of research, with a focus on the development and evaluation of a number of innovative social skills training, cognitive-behavioral relapse prevention, and brief motivationally oriented treatments, including telephone-based interventions, that provide care for populations who might otherwise choose not to seek or may have limited access to treatment. These approaches have targeted behaviors of concern and considerable relevance to the CTN. He currently has a NIDA-funded grant to evaluate the efficacy of a theory-based telephone-delivered brief motivational enhancement intervention for male perpetrators of domestic violence. He is nationally known for his work on developing interventions for the treatment of both adults and adolescents who are dependent on marijuana. He was a member of the multisite Marijuana Treatment Project, one of the largest randomized clinical trials with marijuana users. He currently has NIDA-funded grants to evaluate a “Teen Marijuana Checkup” in which a 2-session motivational enhancement intervention is compared to health education lectures about marijuana or an assessment-only condition with high school students. Dr. Roffman collaborated with Dr. Kathleen Carroll of the New England Node to propose a Marijuana Treatment concept which was ranked 4 th out of 42 concepts proposed in the last wave of CTN review.

Updated 8/2011 · Privacy · Terms
http://adai.washington.edu/ctn/researchers.htm